Zheng Quan Shi Bao·2025-08-20 18:28Core Viewpoint - Lijun Group reported a slight decline in revenue but a significant increase in net profit for the first half of 2025, indicating strong operational efficiency and growth in specific product segments [2][3]. Financial Performance - The company achieved a revenue of 6.272 billion yuan, a year-on-year decrease of 0.17% - Net profit attributable to shareholders was 1.281 billion yuan, a year-on-year increase of 9.4% - Basic earnings per share stood at 1.43 yuan [2]. Product and R&D Development - Major product revenues in the digestive, psychiatric, reproductive, and traditional Chinese medicine sectors all experienced year-on-year growth - R&D investment was approximately 491 million yuan, accounting for 7.82% of total revenue - The company has 39 products in the research pipeline, with 13 in the registration phase and 4 in Phase III clinical trials [2][3]. Business Development and Collaboration - The company introduced 6 projects through business development (BD) in 2024, with 5 successfully entering clinical transformation - The focus for BD in the first half of 2025 included core therapeutic areas such as digestive, psychiatric, metabolic, and anti-infection fields [3]. AI and Patent Strategy - Lijun Group enhanced the application of AI technology throughout the R&D process, including drug design and clinical research - In the first half of 2025, the company submitted 23 patent applications and received 19 domestic patent authorizations, totaling 936 effective patents [3]. International Revenue Growth - The company achieved overseas revenue of approximately 1.004 billion yuan, a year-on-year increase of 18.4% - Overseas revenue accounted for about 16.01% of total revenue, an increase of 2.51 percentage points from the previous year [3].